A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate
The primary objective of this study is to evaluate the efficacy (ACR20) of Rob 803 administered orally once daily for 12 weeks in combination with a stable dose of methotrexate in subjects with moderate or severe active RA.
100 Clinical Results associated with OxyPharma AB
0 Patents (Medical) associated with OxyPharma AB
100 Deals associated with OxyPharma AB
100 Translational Medicine associated with OxyPharma AB